VitaSpring Biomedical Co. Ltd.
VSBC
$0.01
-$0.24-95.56%
OTC PK
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 218.70K | 216.80K | 225.40K | 235.00K | 353.60K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 218.70K | 216.80K | 225.40K | 235.00K | 353.60K |
| Operating Income | -218.70K | -216.80K | -225.40K | -235.00K | -353.60K |
| Income Before Tax | -218.70K | -216.80K | -225.40K | -235.00K | -353.60K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -218.70K | -216.80K | -225.40K | -235.00K | -353.60K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -218.70K | -216.80K | -225.40K | -235.00K | -353.60K |
| EBIT | -218.70K | -216.80K | -225.40K | -235.00K | -353.60K |
| EBITDA | -216.20K | -214.30K | -221.60K | -231.20K | -349.80K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 207.03M | 207.03M | 207.03M | 207.03M | 207.03M |
| Average Diluted Shares Outstanding | 207.03M | 207.03M | 207.03M | 207.03M | 207.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |